TRANSACTIONS GRANTED EARLY TERMINATION: 091195 AND 092295—Continued

Name of acquiring person, name of acquired person, name of acquired entity	PMN No.	Date terminated
Sprint Corporation, Sprint Corporation, Centel Cellular Company of Hickory Limited Partnership	95–2586	09/21/95
Morgan Stanley Capital Partners III, L.P., Stichting ''The SITA Foundation'', SITA Telecommunications Holdings N.V	95–2591	09/21/95
Mercury Production Company, Union Oil Company of California, Union Oil Company of California	95–2225	09/22/95
BASF AG Aktiengesellschaft, IVAX Corporation, IVAX Corporation	95–2490	09/22/95
Lynch Corporation, Alco Standard Corporation, Unisouce Worldwide, Inc., Central Products Company	95–2554	09/22/95
Reliance Steel & Aluminum Co., Preussag AG, Feralloy Reliance Company, L.P	95–2568	09/22/95
Preussag AG, Reliance Steel & Aluminum Co., Feralloy Reliance Company, L.P	95–2569	09/22/95
River Oaks Hospital, Inc., Mr. Manfred George Krukemeyer, Woman's Hospital	95–2598	09/22/95
James A. Pattison, James L. White, III, Duval News Management Company	95–2605	09/22/95
Vista 2000, Inc., American Consumer Products, Inc., American Consumer Products, Inc	95–2633	09/22/95

FOR FURTHER INFORMATION CONTACT:

Sandra M. Peay or Renee A. Horton, Contact Representatives

Federal Trade Commission, Premerger Notification Office, Bureau of Competition, Room 303, Washington, D.C. 20580, (202) 326–3100.

By Direction of the Commission.

Donald S. Clark,

Secretary.

[FR Doc. 95–25980 Filed 10–19–95; 8:45 am]

BILLING CODE 6750–01–M

[Docket No. C–2976]

James H. Haren and International Bartending Institute, Inc.

AGENCY: Federal Trade Commission.

ACTION: Notice of period for public comment on petition to modify consent order.

SUMMARY: James H. Haren, an individual respondent in Docket No. C–2976, and International Bartending Institute, Inc., as successor to International Inventors Inc., East, the corporate respondent in Docket No. C–2976, are subject to an order requiring them, among other things, to give a copy of the order to their ''present of future * * * franchise owners * * * who sell [ ] or promote [ ] the sale of respondents' products or services.'' James H. Haren and International Bartending Institute, Inc. (''IBI'') filed a petition on September 12, 1995, requesting the Commission to reopen and alter, modify or set aside in part the order to the extent that they are required to give a copy of the order to present or future IBI franchise owners. This document announces the public comment period on this petition.

DATES: The deadline for filing comments in this matter is November 13, 1995.

ADDRESSES: Comments should be sent to the Office of the Secretary, Federal Trade Commission, 6th Street and Pennsylvania Avenue, NW., Washington, DC 20580. Requests for copies of the petition should be sent to the Public Reference Branch, Room 130.

FOR FURTHER INFORMATION CONTACT:

Elena Paoli, Attorney, Division of Enforcement, Bureau of Consumer Protection, Federal Trade Commission, Washington, DC 20580, (202) 326–2974.

SUPPLEMENTARY INFORMATION: The order in Docket No. C–2976 was issued on July 5, 1979, and reported at 94 F.T.C. 111. The order prohibited Haren and a new-defunct company, International Inventors, Inc., East, from making various misrepresentations regarding the promotion of inventors' ideas. In 1994, the Federal Trade Commission charged Haren and his current company, IBI, a franchisor of bartending schools, with violating the order in Docket No. C–2976 by not providing a copy of the order to the present and future franchise owners of IBI schools. The complaint also charged Haren and IBI with violating the Commission's rule governing Disclosure Requirements and Prohibitions Concerning Franchising and Business Opportunity Ventures, 16 CFR Part 436. Haren and IBI settled the Commission charges by paying a $50,000 civil penalty and signing a consent decree that was filed in federal district court. *See U.S.* v. *International Bartending Institute, Inc., and James H. Haren*, Civ. No. 94–1104–A (E.D. Va., August 22, 1994).

Haren and IBI argue that changed conditions of fact and the public interest require modifying the order in Docket No. C–2976 because the order only applied to present or future franchisees of International Inventors, Inc., East, and because prospective franchisees of IBI receive full disclosure of the Commission's order in IBI's Uniform Franchise Offering Circular. Haren and IBI argue that prospective IBI franchisees are confused by the order because the order involves an invention promotion company and does not involve a bartending school franchise business.

Donald S. Clark,

Secretary.

[FR Doc. 95–25982 Filed 10–19–95; 8:45 am]

BILLING CODE 6750–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 94C–0338]

Gist-brocades NV; Withdrawal of a Color Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the withdrawal, without prejudice to a future filing, of a color additive petition (CAP 4C0243) proposing that the color additive regulations be amended to provide for the safe use of the inactivated and dried yeast *Phaffia rhodozyma* to provide a pigment source for salmonids.

FOR FURTHER INFORMATION CONTACT: Martha D. Peiperl, Center for Food Safety and Applied Nutrition (HFS–217), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3077.

SUPPLEMENTARY INFORMATION: In a notice published in the Federal Register of October 17, 1994 (59 FR 52306), FDA announced that a color additive petition (CAP 4C0243) had been filed by Gist-brocades NV, Wateringseweg, 2611 XT Delft, The Netherlands. The petition proposed that part 73 *Listing of Color Additives Exempt From Certification* (21 CFR part 73) of the color additive regulations be amended to provide for the safe use of the inactivated and dried yeast *P. rhodozyma* to provide a pigment source for salmonids. Gist-

brocades NV has now withdrawn the petition without prejudice to a future filing (21 CFR 71.6(c)(2)).

Dated: September 22, 1995.

Alan M. Rulis,

Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 95–25971 Filed 10–19–95; 8:45 am]

BILLING CODE 4160–01–F

Advisory Committees; Notice of Meetings

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: This notice announces forthcoming meetings of public advisory committees of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meetings and methods by which interested persons may participate in open public hearings before FDA's advisory committees.

FDA has established an Advisory Committee Information Hotline (the hotline) using a voice-mail telephone system. The hotline provides the public with access to the most current information on FDA advisory committee meetings. The advisory committee hotline, which will disseminate current information and information updates, can be accessed by dialing 1–800–741–8138 or 301–443–0572. Each advisory committee is assigned a 5-digit number. This 5-digit number will appear in each individual notice of meeting. The hotline will enable the public to obtain information about a particular advisory committee by using the committee's 5-digit number. Information in the hotline is preliminary and may change before a meeting is actually held. The hotline will be updated when such changes are made.

MEETINGS: The following advisory committee meetings are announced:

Endocrinologic and Metabolic Drugs Advisory Committee

Date, time, and place. November 16 and 17, 1995, 8 a.m., Holiday Inn—Silver Spring, Plaza Ballroom, 8777 Georgia Ave., Silver Spring, MD.

Type of meeting and contact person. Open public hearing, November 16, 1995, 8 a.m. to 8:30 a.m., unless public participation does not last that long; open committee discussion, 8:30 a.m. to 6 p.m.; open public hearing, November 17, 1995, 8 a.m. to 8:30 a.m., unless public participation does not last that long; open committee discussion, 8:30 a.m. to 4 p.m.; Kathleen R. Reedy, Center for Drug Evaluation and Research (HFD–9), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–5455, FAX 301–443–0699, or FDA Advisory Committee Information Hotline, 1–800–741–8138 (301–443–0572 in the Washington, DC area) Endocrinologic and Metabolic Drugs Advisory Committee, code 12536.

General function of the committee. The committee reviews and evaluates data on the safety and effectiveness of marketed and investigational human drugs for use in endocrine and metabolic disorders.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before November 10, 1995, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

Open committee discussion. On November 16, 1995, in the morning, the committee will hear presentations and discuss data submitted regarding the safety and efficacy of dexfenfluramine hydrochloride, new drug application (NDA) 20–344 (Interneuron Pharmaceuticals, Inc.), for an obesity indication, as followup to the meeting of September 28, 1995. In the afternoon, the committee will hear presentations and discuss data submitted regarding the safety and efficacy of sodium fluoride USP, NDA 19–975 (Slow Fluoride, Texas Southwest Medical Center), for an osteoporosis indication. On November 17, 1995, the committee will discuss data regarding the safety and efficacy of probucol, NDA 17–535 (Lorelco®, Hoechst Marion Roussel), for a lipid altering indication and whether the drug should be withdrawn from the market.

Joint Meeting of the Nonprescription Drugs Advisory Committee and the Pulmonary-Allergy Drugs Advisory Committee

Date, time, and place. November 16, 1995, 8 a.m., Parklawn Bldg., conference rooms D and E, 5600 Fishers Lane, Rockville, MD.

Type of meeting and contact person. Open public hearing, 8 a.m. to 9 a.m., unless public participation does not last that long; open committee discussion, 9 a.m. to 5 p.m.; Lee L. Zwanziger, Liz L. Ortuzar, or Leander B. Madoo, Center for Drug Evaluation and Research (HFD–9), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–4695, or FDA Advisory Committee Information Hotline, 1–800–741–8138 (301–443–0572 in the Washington, DC area), Nonprescription Drugs Advisory Committee, code 12541.

General function of the committees. The Nonprescription Drugs Advisory Committee reviews and evaluates available data concerning the safety and effectiveness of over-the-counter (nonprescription) human drug products for use in the treatment of a broad spectrum of human symptoms and diseases. The Pulmonary-Allergy Drugs Advisory Committee reviews and evaluates data on the safety and effectiveness of marketed and investigational human drugs for use in the treatment of pulmonary disease and diseases with allergic and/or immunologic mechanisms.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before November 10, 1995, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their comments.

Open committee discussion. The committees will first discuss data relevant to investigational new drug (IND) 41,743, sponsored by Sandoz Pharmaceuticals Corp., on the efficacy of clemastine fumarate in the common cold. The committees will then discuss a meta-analysis of data on antihistamines and the common cold to address the inclusion of the common cold indication for the over-the-counter antihistamines, which is currently in the tentative final monograph, in the final monograph.

Joint Meeting of the Nonprescription Drugs Advisory Committee and the Dermatologic and Ophthalmic Drugs Advisory Committee

Date, time, and place. November 17, 1995, 8 a.m., Parklawn Bldg., conference rooms D and E, 5600 Fishers Lane, Rockville, MD.

Type of meeting and contact person. Open public hearing, 8 a.m. to 9 a.m., unless public participation does not last that long; open committee discussion, 9 a.m. to 4 p.m.; Lee L. Zwanziger, Liz L. Ortuzar, or Ermona McGoodwin, Center